Skip to content

Gabapentin Enacarbil

    Brands

    DEA Class;  Rx

    Common Brand Names; Horizant

    • GABA Analogs

    Oral analog of GABA.
    Used for restless legs syndrome, postherpetic and other neuralgias, and adjunctively for partial seizures; orphan drug for amyotrophic lateral sclerosis (ALS).
    Monitor for emerging or worsening suicidal thoughts or actions and/or depression.

    Indicated for moderate-to-severe primary restless legs syndrome

    Indicated for management of postherpetic neuralgia (PHN)

    None

    • Somnolence/sedation (10-27%)
    • Dizziness (13-30%)
    • Headache (7-15%)
    • Fatigue/asthenia (6-10%)
    • Nausea (4-9%)
    • Fatigue/asthenia (6-10%)
    • Peripheral edema (6-7%)
    • Insomnia (3-7%)
    • Irritability (4%)
    • Weight increase (2-5%)
    • Blurred vision (2-5%)
    • Xerostomia (3-4%)
    • Flatulence (2-3%)
    • Vertigo (1-3%)
    • Peripheral edema (1-3%)
    • Drunk/abnormal sensation (1-3%)
    • Depression (1-3%)
    • Decreased libido (1-2%)

    Safety and effectiveness in patients with epilepsy not studied

    Pregnancy Category: C

    Limited available data in pregnancy; use caution

    Lactation: Unknown whether distributed in breast milk

    Adults

    3600 mg/day PO (immediate-release products, e.g., Neurontin); 1800 mg/day PO (extended-release tablets; Gralise ONLY); 1200 mg/day PO (extended-release tablets; Horizant ONLY).

    Geriatric

    3600 mg/day PO (immediate-release products, e.g., Neurontin); 1800 mg/day PO (extended-release tablets; Gralise ONLY); 1200 mg/day PO (extended-release tablets; Horizant ONLY).

    Adolescents

    3600 mg/day PO (immediate-release products, e.g., Neurontin); safety and efficacy of extended-release gabapentin products have not been established.

    Children

    3—12 years: 50 mg/kg/day PO immediate-release products has been suggested, higher dosages occasionally used in refractory patients. Safety and efficacy of extended-release gabapentin products have not been established.
    < 3 years: Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Gabapentin Enacarbil

    tablet, extended-release

    • 300mg
    • 600mg